These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18402796)

  • 1. Severe dilated cardiomyopathy as a consequence of Ecstasy intake.
    Mizia-Stec K; Gasior Z; Wojnicz R; Haberka M; Mielczarek M; Wierzbicki A; Pstraś K; Hartleb M
    Cardiovasc Pathol; 2008; 17(4):250-3. PubMed ID: 18402796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acute hepatitis due to ecstasy].
    Roques V; Perney P; Beaufort P; Hanslik B; Ramos J; Durand L; Le Bricquir Y; Blanc F
    Presse Med; 1998 Mar; 27(10):468-70. PubMed ID: 9767974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case 6 / 2016 - Heart Failure in a 23-Year-Old Male with a History of Illicit Drug Use.
    Ribas FF; Gutierrez PS
    Arq Bras Cardiol; 2016 Dec; 107(6):590-599. PubMed ID: 28558088
    [No Abstract]   [Full Text] [Related]  

  • 4. Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence.
    Gonzalez-Valdes I; Hidalgo I; Bujarrabal A; Lara-Pezzi E; Padron-Barthe L; Garcia-Pavia P; Gómez-del Arco P; Redondo JM; Ruiz-Cabello JM; Jimenez-Borreguero LJ; Enriquez JA; de la Pompa JL; Hidalgo A; Gonzalez S
    Nat Commun; 2015 Mar; 6():6473. PubMed ID: 25751743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option.
    Garbino J; Henry JA; Mentha G; Romand JA
    Vet Hum Toxicol; 2001 Apr; 43(2):99-102. PubMed ID: 11308131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ecstasy (MDMA) and oral health.
    Brand HS; Dun SN; Nieuw Amerongen AV
    Br Dent J; 2008 Jan; 204(2):77-81. PubMed ID: 18268544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of drug-facilitated sexual assault involving 3,4-methylenedioxy-methylamphetamine.
    Eiden C; Cathala P; Fabresse N; Galea Y; Mathieu-Daudé JC; Baccino E; Peyrière H
    J Psychoactive Drugs; 2013; 45(1):94-7. PubMed ID: 23662335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: multidetector CT and pathology findings.
    Lawler LP; Abraham S; Fishman EK
    J Comput Assist Tomogr; 2001; 25(4):649-52. PubMed ID: 11473199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comment on R. Thomasius, M. Schmolke, D. Kraus: MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
    Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H
    Fortschr Neurol Psychiatr; 1999 Dec; 67(12):574-6. PubMed ID: 10683753
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 12. Contraction band necrosis in two ecstasy abusers: a latent lethal lesion associated with ecstasy.
    Hua YS; Liang R; Liang L; Huang GZ
    Am J Forensic Med Pathol; 2009 Sep; 30(3):295-7. PubMed ID: 19696592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is the anxiety about Ecstasy justified?].
    Möller-Nehring E; Luderer HJ
    Fortschr Med; 1997 Mar; 115(7):28, 31-2, 34. PubMed ID: 9173018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports].
    Bango J; Fadón P; Mata F; Rubio G; Santo-Domingo J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):260-3. PubMed ID: 9807860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 16. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL; Shear PK; Corcoran K
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of mild hyponatraemia in females using ecstasy at a rave party.
    van Dijken GD; Blom RE; Hené RJ; Boer WH; NIGRAM Consortium
    Nephrol Dial Transplant; 2013 Sep; 28(9):2277-83. PubMed ID: 23476039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe chronic hepatitis secondary to prolonged use of ecstasy and cocaine.
    Payancé A; Scotto B; Perarnau JM; de Muret A; Bacq Y
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):e109-13. PubMed ID: 23910059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.
    Kouimtsidis C; Schifano F; Sharp T; Ford L; Robinson J; Magee C
    Psychosomatics; 2006; 47(1):86-7. PubMed ID: 16384814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.